Related Experiment Video
Updated: May 28, 2026
09:01
Integrate Imaging Flow Cytometry and Transcriptomic Profiling to Evaluate Altered Endocytic CD1d Trafficking
Published on: October 29, 2018
Revisiting the Ofatumumab Epitope on CD20 through Integrative Molecular Dynamics and Flow Cytometry Analyses
Ana Virgínia F Guimarães1,2, José Samuel S Barbosa1,3, Ana Júlia F Lima1,3
1Protein Engineering and Health Solutions Group, Oswaldo Cruz Foundation, Fiocruz Ceará, Eusébio, Ceará, 61.773-270, Brazil.
Computational and Structural Biotechnology Journal
|May 27, 2026
Summary
Ofatumumab, an anti-CD20 antibody, binds to a specific CD20 epitope. Understanding this interaction refines models and aids in developing new therapies for B-cell malignancies and autoimmune disorders.
Area of Science:
- Immunology
- Structural Biology
- Computational Chemistry
Background:
- Ofatumabatumumab is a fully human anti-CD20 antibody.
- It is utilized in treating B-cell malignancies and autoimmune disorders.
- The precise epitope recognition of ofatumumab remains incompletely defined.
Purpose of the Study:
- To elucidate the structural basis of CD20 binding by ofatumumab.
- To refine the molecular model of ofatumumab single-chain variable fragment-CD20 recognition.
Main Methods:
- Molecular dynamics simulations
- Binding free-energy analyses
- Flow cytometry
Main Results:
- The single-chain variable fragment recognizes a membrane-proximal epitope on extracellular loop 2b/extracellular helix 2.
- Hydrophobic and electrostatic interactions, including the Y105-Y107-Y169 cluster and Arg228, stabilize this binding.
- Mutations at Asp99 and Tyr107 disrupted paratope stability and reduced cellular binding.
Conclusions:
- The study provides atomic-level insights into ofatumumab-CD20 recognition.
- These findings may assist in designing next-generation anti-CD20 therapeutics.
- The results can also inform the development of chimeric antigen receptor T-cell therapies.
